annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 6F Association between deficient mismatch repair system and efficacy to
irinotecan containing first-line chemotherapy in patients with sporadic
metastatic colorectal cancer. (Abstract #3579)
J. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. Kim
Brd. 6G Detector-C: A blood-based IVD with high sensitivity and specificity for early
detection of colorectal cancer. (Abstract #3580)
A. Rosenthal, D. Nuernberg, M. Pross, J. Pertschy, P. Nartschik, T. Manger,
B. Unger, W. Pommerien, H. Adams
Brd. 6H Correlation between bevacizumab-related hypertension and response in
mCRC patients. (Abstract #3581)
A. De Stefano, L. Cannella, C. Carlomagno, A. Crispo, R. Bianco, R. Marciano,
S. Pepe, S. De Placido
Brd. 7A Personalized adjuvant chemotherapy for colorectal cancer based on an
individual 50% inhibitory area under the concentration curve using collagen
gel droplet embedded culture-drug sensitivity test. (Abstract #3582)
T. Ochiai, K. Nishimura, T. Watanabe, M. Kitajima, T. Hashiguchi, A. Nakatani,
A. Muraki, N. Sakuyama, S. Futagawa, I. Nagaoka
Brd. 7B Genetic polymorphism associated with chronic neurotoxicity and recurrence
in curatively-resected colon cancer patients receiving oxaliplatin-based
adjuvant chemotherapy. (Abstract #3583)
S. Lee, H. Won, E. Son, J. Lee, S. Park, J. Park, Y. Park, H. Lim, W. Kang
Brd. 7C Are MGMT promoter methylation and EGFR mutations early markers of
tumor progression in colorectal cancer? (Abstract #3584)
T. Wenner, B. Metzger, L. Chambeau, G. Mahon, M. Pauly, J. Kaiser,
G. J. Berchem, M. Dicato
Brd. 7D Prospective study of paresthetic neurotoxicity from oxaliplatin-based
regimens in the treatment of colorectal cancer. (Abstract #3585)
X. S. Wang, D. R. Fogelman, C. Eng, M. Malekifar, R. J. Reynolds, N. A. Shah,
T. R. Mendoza, K. Y. Glover, P. M. Dougherty, C. S. Cleeland
Brd. 7E Prognostic values of micrornas in patients with Dukes’ B and C colon cancer.
(Abstract #3586)
M. Karaayvaz, T. Pal, B. Song, C. Zhang, P. Geogakopoulos, S. Mehmood,
S. Burke, K. Shroyer, J. Ju
Brd. 7F Vascular endothelial growth factor polymorphisms and clinical outcome in
colorectal cancer patients treated with irinotecan-based chemotherapy and
bevacizumab in the first-line setting. (Abstract #3587)
A. Koutras, A. Antonacopoulou, F. Fostira, E. C. Briasoulis, I. Sgouros,
A. Koumarianou, N. Xiros, C. Christodoulou, G. Fountzilas, H. Kalofonos
Brd. 7G New insights to gene expression signatures from primary FFPE tumors for
the prediction of response to cetuximab in KRAS and BRAF wild-type
colorectal cancer (CRC). (Abstract #3588)
E. Budinska, M. Delorenzi, W. De Roock, B. Jacobs, S. Walker, C. Wilson,
T. Davison, R. D. Kennedy, S. Tejpar
Brd. 7H Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is
not representative of their status in related metastases. (Abstract #3589)
P. Cejas, M. Lopez-Gomez, C. Aguayo, R. Madero, J. De Castro, C. Belda-Iniesta,
J. Barriuso, E. Burgos, M. Gonzalez-Baron, J. Feliu
Brd. 8A Association of GRP78 polymorphisms with response and TTP in patients
with mCRC treated with FOLFOX/BV or XELOX/BV. (Abstract #3590)
H. Lenz, W. Zhang, D. Yang, A. B. El-Khoueiry, Y. Ning, A. Pohl, P. O. Bohanes,
K. D. Danenberg, T. Winder
Brd. 8B Lessons from PETACC 2: No prognostic impact of KRAS-/BRAF-status in
stage III colon cancer treated with adjuvant 5-FU monotherapy. (Abstract
#3591)
D. E. Aust, M. P. Lutz, M. Mauer, I. Popov, G. B. Baretton, L. Bedenne, A. Carrato,
C. Kohne
260